• Publications
  • Influence
Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
TLDR
Raloxifene has promise as an agent with beneficial bone and cardiovascular effects in the absence of significant uterine effects, and ethynyl estradiol diverged dramatically from estrogen in its lack of significant estrogenic effects on uterine tissue. Expand
Phospholipid Transfer Protein Is Regulated by Liver X Receptors in Vivo *
TLDR
It is concluded that PLTP is a direct target gene of LXRs in vivo and plays an important role in LXR agonist-mediated HDL cholesterol and size increase in mice. Expand
Cation transport and specificity of ionomycin. Comparison with ionophore A23187 in rat liver mitochondria.
TLDR
In conclusion, ionomycin was shown to be an effective ionophore for Ca2+ in rat liver mitochondria and mediated an efflux of K+ provided that the mitochondria were depleted of their endogenous divalent metal ions. Expand
Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits.
TLDR
The findings indicate that raloxifene hydrochloride has a potentially important antiatherogenic effect, analogous to that observed with estrogen in this model. Expand
Losartan, a nonpeptide angiotensin II (Ang II) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries.
TLDR
Losartan attenuated the vascular response to balloon catheter injury, and this effect was associated with functional block of vascular AT1 receptors, supporting a role for Ang II, acting via AT1 receptor, in myointimal thickening subsequent to balloon injury of rat carotid arteries. Expand
Cholesteryl Ester Transfer Protein Expression Prevents Diet-Induced Atherosclerotic Lesions in Male db/db Mice
TLDR
The expression of human CETP in db/db mice prevented the formation of diet-induced lesions, suggesting an antiatherogenic effect of CETP on vascular health in the context of diabetic obesity. Expand
LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum.
TLDR
Results suggest that LY195115-sensitive PDE is located within sarcoplasmic reticulum membranes with a distribution similar or identical to that of Ca2+-ATPase, and is referred to as SR-PDE. Expand
Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol‐fed rabbits
TLDR
Plasma raloxifene concentrations were low relative to those obtained in ralOXifene‐treated women, so the effects of ral oxifene at higher doses are investigated. Expand
Identification of a Novel Selective Peroxisome Proliferator-Activated Receptor α Agonist, 2-Methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic Acid
TLDR
LY518674 is a potent and selective PPARα agonist that produced a much greater increase in serum HDL-c than the known fibrate drugs. Expand
In vitro vascular relaxation by new inotropic agents: relationship to phosphodiesterase inhibition and cyclic nucleotides.
TLDR
Vascular relaxation was examined further for a series of novel dihydropyridazinones, and relaxant potencies correlated directly with the ability of these agents to inhibit an isozyme of cyclic nucleotide phosphodiesterase (PDE) located in the sarcoplasmic reticulum of cardiac muscle. Expand
...
1
2
3
4
5
...